Four Phase 3 clinical trials of baricitinib in the treatment of moderate-to-severe active rheumatoid arthritis enrolled patients who were methotrexate-naïve or had inadequate response to methotrexate, conventional disease-modifying antirheumatic drugs (DMARDs) or DMARDs with TNF inhibitors.
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
Dr. Taniguchi aimed to describe the pathomechanism of induction of severe airway symptoms in AERD patients and described potential mechanisms of anti-IgE (omalizumab) as a treatment for AERD.
Omalizumab therapy was associated with reduced exacerbation and hospitalization rates in US clinics, according to findings from the prospective multicenter observational registry PROSPERO study
AAN 2016 General News
Treatment with oral dexamethasone for 4 days significantly improved pain levels in the majority of outpatients with status migrainosus, a retrospective chart review presented at the 68th AAN Annual Meeting has found.